Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients

HIV Medicine

Volumn 12, Issue 8, 2011, Pages 506-509

  Trimoulet, Pascale ^a   Belzunce, C ^a   Faure, M ^a   Wittkop, L ^b   Reigadas, S ^a   Dupon, M ^a   Ragnaud, J M ^a   Fleury, H ^a   Neau, D ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

HCV protease; HCV protease inhibitor resistance; HIV HCV coinfected patients

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ARTICLE; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; PREVALENCE; PRIORITY JOURNAL; VIRAL GENETICS; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80051599715     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00913.x     Document Type: Article

References (11)

1. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
2. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
3. Sarrazin C, Rouzier R, Wagner F et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 non responders. Gastroenterology 2007; 132: 1270-1278.
4. Thompson AJV, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009; 16: 377-387.
5. Sarrazin C, Kieffer T, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
6. Nunez M, Miralles C, Berdun MA et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972-982.
7. Legrand E, Neau D, Galperine T et al. CD4T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment. J Infect Dis 2002; 186: 302-311.
8. Morsica G, Bagaglio S, Uberti-Foppa C, Galli L, Lazzarin A. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV-HCV coinfected individuals treated with antiretroviral therapy. J AIDS 2009; 51: 106-108.
9. Halfon P, Bourliere M, Khiri H et al. Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy. AIDS 2008; 22: 1694-1696.
10. Dabis F, Chêne G, Salamon RGECSA. Hospital-based surveillance of HIV infection: Bordeaux, France, 1983-1990. AIDS 1991; 5: 774-775.
11. Zhou Y, Bartels DJ, Hanzelka BL et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2008; 52: 110-120.